Personalis Inc PSNL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PSNL is a good fit for your portfolio.
News
-
Personalis to Announce First Quarter 2024 Financial Results
-
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
-
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
-
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
Trading Information
- Previous Close Price
- $1.38
- Day Range
- $1.30–1.38
- 52-Week Range
- $0.89–2.60
- Bid/Ask
- $1.28 / $1.41
- Market Cap
- $66.57 Mil
- Volume/Avg
- 1 / 336,071
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.85
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 225
- Website
- https://www.personalis.com
Comparables
Valuation
Metric
|
PSNL
|
TIHE
|
MRVI
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 150.00 |
Price/Book Value | 0.51 | — | 2.43 |
Price/Sales | 0.85 | — | 3.50 |
Price/Cash Flow | — | — | 35.65 |
Price/Earnings
PSNL
TIHE
MRVI
Financial Strength
Metric
|
PSNL
|
TIHE
|
MRVI
|
---|---|---|---|
Quick Ratio | 2.79 | — | 7.21 |
Current Ratio | 3.11 | — | 8.00 |
Interest Coverage | −1,036.40 | — | 13.86 |
Quick Ratio
PSNL
TIHE
MRVI
Profitability
Metric
|
PSNL
|
TIHE
|
MRVI
|
---|---|---|---|
Return on Assets (Normalized) | −32.88% | — | −30.00% |
Return on Equity (Normalized) | −47.92% | — | −126.21% |
Return on Invested Capital (Normalized) | −39.54% | — | −41.97% |
Return on Assets
PSNL
TIHE
MRVI
Diagnostics & Research Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Zcdkgsfv | Rygb | $209.3 Bil | |
DHR
| Danaher Corp | Ygmsdscbwj | Vdbyxw | $185.5 Bil | |
IQV
| IQVIA Holdings Inc | Lbvvrnsjk | Ywggbs | $43.4 Bil | |
IDXX
| IDEXX Laboratories Inc | Hbzzktdkwf | Fnlzmh | $41.0 Bil | |
A
| Agilent Technologies Inc | Wkvjhtrdz | Bbmbh | $40.3 Bil | |
MTD
| Mettler-Toledo International Inc | Mdvcfhdr | Cxrbps | $26.4 Bil | |
ICLR
| Icon PLC | Bqwbtdv | Kpjyttf | $25.2 Bil | |
ILMN
| Illumina Inc | Xhrbpnznw | Cffwp | $19.6 Bil | |
WAT
| Waters Corp | Dybnpgyz | Gdw | $18.0 Bil | |
LH
| Laboratory Corp of America Holdings | Pwgsvzjqfv | Ybszfl | $17.5 Bil |